On this episode, we welcome back Henry So, clinical pharmacist for Diamond's OPTICS team. As we recorded this, Henry was days away from giving an NCCHC conference presentation on evaluating high cost therapies for type 2 diabetes patients. We discuss why he was inspired to develop a presentation around this topic, look at the use of different diabetic agents in special patient populations, and dive into his clinical rationale for helping providers choose between newer often pricier agents and older more established therapies. If you missed Henry’s presentation at NCCHC, you can catch up with this podcast. Links to studies mentioned in the show/futher reading: Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | New England Journal of Medicine Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes | New England  ...